Innoviva Inc(NASDAQ:INVA) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Jul 28, 2016. Company reported revenue of $32.47M. Analysts estimated a revenue of $31.13M. Earnings per share were $0.17. Analysts had estimated an EPS of $0.11.
Several Insider Transactions has been reported to the SEC. On May 20, 2016, James L Tyree (director) sold 813 shares at $10.47 per share price.
Innoviva Inc. formerly Theravance Inc. is an asset management company that is focused on the development commercialization and financial management of bio-pharmaceuticals. The Company is focused on managing its respiratory assets partnered with Glaxo Group Limited (GSK) including RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol FF/VI) and ANORO ELLIPTA (umeclidinium bromide/ vilanterol UMEC/VI) with the intention of providing capital returns to stockholders. Its RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of vilanterol (VI) a long-acting beta2 agonist (LABA) and fluticasone furoate (FF) an inhaled corticosteroid (FF/VI) delivered through the ELLIPTA dry powder inhaler. Its ANORO ELLIPTA is a dual bronchodilator consisting of umeclidinium (UMEC) a long-acting muscarinic antagonist (LAMA) and vilanterol (VI) which is used for the treatment of chronic obstructive pulmonary diseases (COPD).